The data refers to isolates non-susceptible to the designated antimicrobials. The figures for methicillin refer to methicillin-resistant Staphylococcus aureus (MRSA), which are all positive for the mecA gene.
| Year (September to August) | Total | Methicillin | Erythromycin | Clindamycin | Gentamicin | Cotrimoxazole | Minocycline | Tetracycline | Chloramphenicol | Ciprofloxacin | Rifampicin | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | ||||||||||||||||||||||
| No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | ||
| 2009 / 2010 | 57 | 50 | 87.7 | - | - | 51 | 89.5 | - | - | 57 | 100.0 | - | - | 57 | 100.0 | - | - | 11 | 19.3 | - | - | 3 | 5.3 | - | - | 56 | 98.2 | - | - | 49 | 86.0 | - | - | 55 | 96.5 | - | - | 3 | 5.3 | - | - |
| 2010 / 2011 | 21 | 15 | 71.4 | - | - | 21 | 100.0 | - | - | 21 | 100.0 | - | - | 20 | 95.2 | - | - | 3 | 14.3 | - | - | 1 | 4.8 | - | - | 21 | 100.0 | - | - | 20 | 95.2 | - | - | 17 | 81.0 | - | - | 0 | 0.0 | - | - |
| 2011 / 2012 | 34 | 30 | 88.2 | - | - | 33 | 97.1 | - | - | 33 | 97.1 | - | - | 34 | 100.0 | - | - | 2 | 5.9 | - | - | 3 | 8.8 | - | - | 32 | 94.1 | - | - | 33 | 97.1 | - | - | 31 | 91.2 | - | - | 1 | 2.9 | - | - |
| 2012 / 2013 | 27 | 21 | 77.8 | - | - | 27 | 100.0 | - | - | 27 | 100.0 | - | - | 25 | 92.6 | - | - | 7 | 25.9 | - | - | 1 | 3.7 | - | - | 27 | 100.0 | - | - | 26 | 96.3 | - | - | 25 | 92.6 | - | - | 0 | 0.0 | - | - |
| 2013 / 2014 | 16 | 7 | 43.8 | - | - | 15 | 93.8 | - | - | 15 | 93.8 | - | - | 15 | 93.8 | - | - | 3 | 18.8 | - | - | 11 | 68.8 | - | - | 14 | 87.5 | - | - | 12 | 75.0 | - | - | 11 | 68.8 | - | - | 0 | 0.0 | - | - |
| 2014 / 2015 | 8 | 3 | 37.5 | - | - | 4 | 50.0 | - | - | 6 | 75.0 | - | - | 3 | 37.5 | - | - | 1 | 12.5 | - | - | 0 | 0.0 | - | - | 8 | 100.0 | - | - | 7 | 87.5 | - | - | 4 | 50.0 | - | - | 0 | 0.0 | - | - |
| 2015 / 2016 | 2 | 2 | 100.0 | - | - | 1 | 50.0 | - | - | 2 | 100.0 | - | - | 2 | 100.0 | - | - | 1 | 50.0 | - | - | 1 | 50.0 | - | - | 2 | 100.0 | - | - | 2 | 100.0 | - | - | 2 | 100.0 | - | - | 0 | 0.0 | - | - |
| 2016 / 2017 | 11 | 5 | 45.5 | - | - | 8 | 72.7 | - | - | 10 | 90.9 | - | - | 10 | 90.9 | - | - | 5 | 45.5 | - | - | 3 | 27.3 | - | - | 10 | 90.9 | - | - | 11 | 100.0 | - | - | 11 | 100.0 | - | - | 0 | 0.0 | - | - |
| 2017 / 2018 | 7 | 5 | 71.4 | - | - | 7 | 100.0 | - | - | 7 | 100.0 | - | - | 6 | 85.7 | - | - | 0 | 0.0 | - | - | 2 | 28.6 | - | - | 7 | 100.0 | - | - | 7 | 100.0 | - | - | 6 | 85.7 | - | - | 0 | 0.0 | - | - |
| 2018 / 2019 | 3 | 0 | 0.0 | - | - | 3 | 100.0 | - | - | 3 | 100.0 | - | - | 3 | 100.0 | - | - | 1 | 33.3 | - | - | 2 | 66.7 | - | - | 3 | 100.0 | - | - | 3 | 100.0 | - | - | 2 | 66.7 | - | - | 0 | 0.0 | - | - |
| 2019 / 2020 | 12 | 5 | 41.7 | - | - | 10 | 83.3 | - | - | 10 | 83.3 | - | - | 7 | 58.3 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 11 | 91.7 | - | - | 9 | 75.0 | - | - | 8 | 66.7 | - | - | 0 | 0.0 | - | - |
| 2020 / 2021 | 11 | 4 | 36.4 | - | - | 10 | 90.9 | - | - | 11 | 100.0 | - | - | 10 | 90.9 | - | - | 0 | 0.0 | - | - | 1 | 9.1 | - | - | 11 | 100.0 | - | - | 11 | 100.0 | - | - | 9 | 81.8 | - | - | 0 | 0.0 | - | - |
| 2021 / 2022 | 9 | 2 | 22.2 | - | - | 9 | 100.0 | - | - | 9 | 100.0 | - | - | 5 | 55.6 | - | - | 0 | 0.0 | - | - | 4 | 44.4 | - | - | 9 | 100.0 | - | - | 7 | 77.8 | - | - | 6 | 66.7 | - | - | 0 | 0.0 | - | - |
| 2022 / 2023 | 8 | 3 | 37.5 | - | - | 7 | 87.5 | - | - | 7 | 87.5 | - | - | 6 | 75.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 8 | 100.0 | - | - | 8 | 100.0 | - | - | 7 | 87.5 | - | - | 0 | 0.0 | - | - |
| 2023 / 2024 | 9 | 5 | 55.6 | - | - | 9 | 100.0 | - | - | 9 | 100.0 | - | - | 9 | 100.0 | - | - | 0 | 0.0 | - | - | 5 | 55.6 | - | - | 9 | 100.0 | - | - | 7 | 77.8 | - | - | 7 | 77.8 | - | - | 0 | 0.0 | - | - |
| 2024 / 2025 | 19 | 10 | 52.6 | 10 | 52.6 | 17 | 89.5 | 10 | 52.6 | 17 | 89.5 | 10 | 52.6 | 14 | 73.7 | 8 | 42.1 | 1 | 5.3 | 0 | 0.0 | 11 | 57.9 | 0 | 0.0 | 17 | 89.5 | 10 | 52.6 | 18 | 94.7 | 9 | 47.4 | 16 | 84.2 | 9 | 47.4 | 0 | 0.0 | 0 | 0.0 |
| Year (September to August) | Total | Methicillin | Erythromycin | Clindamycin | Gentamicin | Cotrimoxazole | Minocycline | Tetracycline | Chloramphenicol | Ciprofloxacin | Rifampicin | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | ||||||||||||||||||||||
| No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | ||
| 2009 / 2010 | 19 | 0 | 0.0 | - | - | 18 | 94.7 | - | - | 18 | 94.7 | - | - | 3 | 15.8 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 19 | 100.0 | - | - | 0 | 0.0 | - | - | 18 | 94.7 | - | - | 0 | 0.0 | - | - |
| 2010 / 2011 | 12 | 1 | 8.3 | - | - | 12 | 100.0 | - | - | 9 | 75.0 | - | - | 4 | 33.3 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 12 | 100.0 | - | - | 6 | 50.0 | - | - | 12 | 100.0 | - | - | 0 | 0.0 | - | - |
| 2011 / 2012 | 8 | 0 | 0.0 | - | - | 5 | 62.5 | - | - | 5 | 62.5 | - | - | 3 | 37.5 | - | - | 0 | 0.0 | - | - | 1 | 12.5 | - | - | 8 | 100.0 | - | - | 3 | 37.5 | - | - | 8 | 100.0 | - | - | 0 | 0.0 | - | - |
| 2012 / 2013 | 1 | 0 | 0.0 | - | - | 1 | 100.0 | - | - | 1 | 100.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 100.0 | - | - | 0 | 0.0 | - | - | 1 | 100.0 | - | - | 0 | 0.0 | - | - |
| 2013 / 2014 | 4 | 0 | 0.0 | - | - | 4 | 100.0 | - | - | 4 | 100.0 | - | - | 2 | 50.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 2 | 50.0 | - | - | 2 | 50.0 | - | - | 4 | 100.0 | - | - | 0 | 0.0 | - | - |
| 2014 / 2015 | 17 | 0 | 0.0 | - | - | 11 | 64.7 | - | - | 7 | 41.2 | - | - | 4 | 23.5 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 17 | 100.0 | - | - | 5 | 29.4 | - | - | 17 | 100.0 | - | - | 1 | 5.9 | - | - |
| 2015 / 2016 | 9 | 0 | 0.0 | - | - | 4 | 44.4 | - | - | 4 | 44.4 | - | - | 2 | 22.2 | - | - | 0 | 0.0 | - | - | 1 | 11.1 | - | - | 9 | 100.0 | - | - | 0 | 0.0 | - | - | 9 | 100.0 | - | - | 0 | 0.0 | - | - |
| 2016 / 2017 | 18 | 0 | 0.0 | - | - | 8 | 44.4 | - | - | 8 | 44.4 | - | - | 8 | 44.4 | - | - | 1 | 5.6 | - | - | 3 | 16.7 | - | - | 18 | 100.0 | - | - | 8 | 44.4 | - | - | 18 | 100.0 | - | - | 0 | 0.0 | - | - |
| 2017 / 2018 | 1 | 0 | 0.0 | - | - | 1 | 100.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 100.0 | - | - | 0 | 0.0 | - | - | 1 | 100.0 | - | - | 0 | 0.0 | - | - |
| 2018 / 2019 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2019 / 2020 | 5 | 0 | 0.0 | - | - | 5 | 100.0 | - | - | 4 | 80.0 | - | - | 4 | 80.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 5 | 100.0 | - | - | 4 | 80.0 | - | - | 5 | 100.0 | - | - | 0 | 0.0 | - | - |
| 2020 / 2021 | 14 | 1 | 7.1 | - | - | 14 | 100.0 | - | - | 14 | 100.0 | - | - | 1 | 7.1 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 12 | 85.7 | - | - | 0 | 0.0 | - | - | 13 | 92.9 | - | - | 0 | 0.0 | - | - |
| 2021 / 2022 | 6 | 0 | 0.0 | - | - | 6 | 100.0 | - | - | 6 | 100.0 | - | - | 4 | 66.7 | - | - | 1 | 16.7 | - | - | 0 | 0.0 | - | - | 6 | 100.0 | - | - | 4 | 66.7 | - | - | 6 | 100.0 | - | - | 0 | 0.0 | - | - |
| 2022 / 2023 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2023 / 2024 | 5 | 0 | 0.0 | - | - | 5 | 100.0 | - | - | 5 | 100.0 | - | - | 3 | 60.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 4 | 80.0 | - | - | 3 | 60.0 | - | - | 5 | 100.0 | - | - | 0 | 0.0 | - | - |
| 2024 / 2025 | 2 | 0 | 0.0 | 0 | 0.0 | 2 | 100.0 | 2 | 100.0 | 2 | 100.0 | 2 | 100.0 | 2 | 100.0 | 2 | 100.0 | 2 | 100.0 | 2 | 100.0 | 0 | 0.0 | 0 | 0.0 | 2 | 100.0 | 2 | 100.0 | 2 | 100.0 | 2 | 100.0 | 2 | 100.0 | 2 | 100.0 | 0 | 0.0 | 0 | 0.0 |
| Year (September to August) | Total | Methicillin | Erythromycin | Clindamycin | Gentamicin | Cotrimoxazole | Minocycline | Tetracycline | Chloramphenicol | Ciprofloxacin | Rifampicin | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | ||||||||||||||||||||||
| No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | ||
| 2009 / 2010 | 15 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 6.7 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 6.7 | - | - | 0 | 0.0 | - | - |
| 2010 / 2011 | 27 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2011 / 2012 | 28 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2012 / 2013 | 16 | 0 | 0.0 | - | - | 2 | 12.5 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2013 / 2014 | 15 | 0 | 0.0 | - | - | 1 | 6.7 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2014 / 2015 | 27 | 0 | 0.0 | - | - | 2 | 7.4 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2015 / 2016 | 7 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2016 / 2017 | 17 | 0 | 0.0 | - | - | 3 | 17.6 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 3 | 17.6 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2017 / 2018 | 13 | 0 | 0.0 | - | - | 1 | 7.7 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 2 | 15.4 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2018 / 2019 | 6 | 0 | 0.0 | - | - | 1 | 16.7 | - | - | 1 | 16.7 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2019 / 2020 | 4 | 1 | 25.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2020 / 2021 | 7 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 14.3 | - | - | 0 | 0.0 | - | - | 1 | 14.3 | - | - | 0 | 0.0 | - | - |
| 2021 / 2022 | 7 | 0 | 0.0 | - | - | 2 | 28.6 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 14.3 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2022 / 2023 | 5 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2023 / 2024 | 4 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 25.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2024 / 2025 | 7 | 0 | 0.0 | 0 | 0.0 | 1 | 14.3 | 1 | 14.3 | 1 | 14.3 | 1 | 14.3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Year (September to August) | Total | Methicillin | Erythromycin | Clindamycin | Gentamicin | Cotrimoxazole | Minocycline | Tetracycline | Chloramphenicol | Ciprofloxacin | Rifampicin | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | ||||||||||||||||||||||
| No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | ||
| 2009 / 2010 | 44 | 0 | 0.0 | - | - | 3 | 6.8 | - | - | 3 | 6.8 | - | - | 5 | 11.4 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 8 | 18.2 | - | - | 0 | 0.0 | - | - | 1 | 2.3 | - | - | 0 | 0.0 | - | - |
| 2010 / 2011 | 20 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 5 | 25.0 | - | - | 0 | 0.0 | - | - | 1 | 5.0 | - | - | 0 | 0.0 | - | - |
| 2011 / 2012 | 14 | 0 | 0.0 | - | - | 1 | 7.1 | - | - | 1 | 7.1 | - | - | 1 | 7.1 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 2 | 14.3 | - | - | 1 | 7.1 | - | - | 1 | 7.1 | - | - | 0 | 0.0 | - | - |
| 2012 / 2013 | 19 | 0 | 0.0 | - | - | 3 | 15.8 | - | - | 2 | 10.5 | - | - | 1 | 5.3 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 5 | 26.3 | - | - | 1 | 5.3 | - | - | 2 | 10.5 | - | - | 0 | 0.0 | - | - |
| 2013 / 2014 | 11 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 9.1 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 3 | 27.3 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2014 / 2015 | 22 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 4.5 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2015 / 2016 | 4 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 25.0 | - | - | 0 | 0.0 | - | - | 1 | 25.0 | - | - | 0 | 0.0 | - | - |
| 2016 / 2017 | 15 | 0 | 0.0 | - | - | 3 | 20.0 | - | - | 3 | 20.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 6 | 40.0 | - | - | 0 | 0.0 | - | - | 1 | 6.7 | - | - | 0 | 0.0 | - | - |
| 2017 / 2018 | 16 | 1 | 6.3 | - | - | 3 | 18.8 | - | - | 3 | 18.8 | - | - | 3 | 18.8 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 2 | 12.5 | - | - | 0 | 0.0 | - | - |
| 2018 / 2019 | 13 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 7.7 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2019 / 2020 | 5 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 20.0 | - | - | 0 | 0.0 | - | - | 1 | 20.0 | - | - | 0 | 0.0 | - | - |
| 2020 / 2021 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2021 / 2022 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2022 / 2023 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2023 / 2024 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2024 / 2025 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Year (September to August) | Total | Methicillin | Erythromycin | Clindamycin | Gentamicin | Cotrimoxazole | Minocycline | Tetracycline | Chloramphenicol | Ciprofloxacin | Rifampicin | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | Intermediate + Resistant (I+R) | Resistant Only (R)* | ||||||||||||||||||||||
| No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | ||
| 2009 / 2010 | 30 | 0 | 0.0 | - | - | 3 | 10.0 | - | - | 2 | 6.7 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 7 | 23.3 | - | - | 1 | 3.3 | - | - | 1 | 3.3 | - | - | 0 | 0.0 | - | - |
| 2010 / 2011 | 8 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2011 / 2012 | 10 | 0 | 0.0 | - | - | 1 | 10.0 | - | - | 1 | 10.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 3 | 30.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2012 / 2013 | 20 | 0 | 0.0 | - | - | 1 | 5.0 | - | - | 1 | 5.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 5.0 | - | - | 0 | 0.0 | - | - |
| 2013 / 2014 | 4 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 25.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2014 / 2015 | 9 | 0 | 0.0 | - | - | 1 | 11.1 | - | - | 0 | 0.0 | - | - | 1 | 11.1 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 11.1 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2015 / 2016 | 1 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2016 / 2017 | 7 | 0 | 0.0 | - | - | 3 | 42.9 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 14.3 | - | - | 0 | 0.0 | - | - | 2 | 28.6 | - | - | 0 | 0.0 | - | - |
| 2017 / 2018 | 6 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2018 / 2019 | 5 | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - |
| 2019 / 2020 | 3 | 0 | 0.0 | - | - | 1 | 33.3 | - | - | 1 | 33.3 | - | - | 0 | 0.0 | - | - | 0 | 0.0 | - | - | 1 | 33.3 | - | - | 1 | 33.3 | - | - | 1 | 33.3 | - | - | 1 | 33.3 | - | - | 0 | 0.0 | - | - |
| 2020 / 2021 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2021 / 2022 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2022 / 2023 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2023 / 2024 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2024 / 2025 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |